Kovitz Investment Group Partners LLC Invests $384,000 in Liquidia Technologies, Inc. $LQDA

Key Points

• Kovitz Investment Group Partners LLC has acquired 26,000 shares of Liquidia Technologies, valued at approximately $384,000, as per a recent 13F filing.
• Several hedge funds have significantly increased their stakes in Liquidia Technologies, with Wells Fargo boosting its stake by 69.1% and Invesco by an astounding 2,675.0%.
• Liquidia Technologies reported a revenue increase of 141.5% year-over-year, with quarterly earnings missing estimates at ($0.49) EPS, compared to a consensus estimate of ($0.43).

Kovitz Investment Group Partners LLC acquired a new position in shares of Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 26,000 shares of the company's stock, valued at approximately $384,000.

Several other large investors have also made changes to their positions in the business. Cetera Investment Advisers grew its stake in shares of Liquidia Technologies by 4.3% in the 4th quarter. Cetera Investment Advisers now owns 31,243 shares of the company's stock valued at $367,000 after purchasing an additional 1,277 shares during the period. Deutsche Bank AG grew its position in Liquidia Technologies by 53.4% during the 4th quarter. Deutsche Bank AG now owns 51,075 shares of the company's stock worth $601,000 after acquiring an additional 17,790 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Liquidia Technologies during the 4th quarter worth approximately $218,000. Millennium Management LLC bought a new stake in Liquidia Technologies during the 4th quarter worth approximately $526,000. Finally, GAMMA Investing LLC grew its position in Liquidia Technologies by 2,342.7% during the 1st quarter. GAMMA Investing LLC now owns 43,675 shares of the company's stock worth $644,000 after acquiring an additional 41,887 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

Insiders Place Their Bets

In other Liquidia Technologies news, CFO Michael Kaseta sold 30,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $20.00, for a total transaction of $600,000.00. Following the completion of the sale, the chief financial officer directly owned 376,412 shares in the company, valued at $7,528,240. This trade represents a 7.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Sarah Krepp sold 2,673 shares of Liquidia Technologies stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $14.28, for a total transaction of $38,170.44. Following the completion of the sale, the insider owned 142,499 shares of the company's stock, valued at approximately $2,034,885.72. The trade was a 1.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,277 shares of company stock worth $1,469,392 in the last three months. Insiders own 26.50% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. HC Wainwright increased their price target on Liquidia Technologies from $29.00 to $35.00 and gave the stock a "buy" rating in a research report on Wednesday, May 28th. Scotiabank increased their price target on Liquidia Technologies from $36.00 to $37.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, May 28th. Needham & Company LLC increased their price target on Liquidia Technologies from $32.00 to $36.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Wells Fargo & Company increased their price target on Liquidia Technologies from $25.00 to $31.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 13th. Finally, Jefferies Financial Group assumed coverage on Liquidia Technologies in a report on Friday, August 15th. They set a "buy" rating and a $43.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $32.11.

Liquidia Technologies Trading Up 1.0%

Shares of LQDA stock traded up $0.27 during trading hours on Wednesday, reaching $28.00. The company had a trading volume of 1,601,048 shares, compared to its average volume of 3,167,636. The company has a 50 day moving average of $18.33 and a 200 day moving average of $16.20. The company has a debt-to-equity ratio of 9.84, a current ratio of 2.49 and a quick ratio of 2.41. The firm has a market cap of $2.41 billion, a price-to-earnings ratio of -16.47 and a beta of 0.14. Liquidia Technologies, Inc. has a 1-year low of $8.75 and a 1-year high of $28.82.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.06). The firm had revenue of $8.84 million during the quarter, compared to the consensus estimate of $3.90 million. Liquidia Technologies had a negative net margin of 732.17% and a negative return on equity of 232.96%. The business's quarterly revenue was up 141.5% on a year-over-year basis. On average, equities research analysts anticipate that Liquidia Technologies, Inc. will post -1.51 EPS for the current year.

Liquidia Technologies Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).